DOCSLIB.ORG

Xenon and Isoflurane Reduce Left Ventricular Remodeling After Myocardial Infarction in the Rat

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Xenon and Isoflurane Reduce Left Ventricular Remodeling After Myocardial Infarction in the Rat PERIOPERATIVE MEDICINE Xenon and Isoflurane Reduce Left Ventricular Remodeling after Myocardial Infarction in the Rat Anna B. Roehl, M.D.,* Sandra Funcke, M.D.,† Michael M. Becker, M.D.,‡ Andreas Goetzenich, M.D.,§ Christian Bleilevens, M.Sc.,|| Rolf Rossaint, M.D.,# Paul Steendijk, M.D., Ph.D.,** Marc Hein, M.D.* ABSTRACT What We Already Know about This Topic • Previous studies have demonstrated that xenon and isoflu- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/118/6/1385/260290/20130600_0-00026.pdf by guest on 24 September 2021 Background: Xenon and isoflurane are known to have car- rane have cardioprotective properties. • However, little is known about the long-term effects of xenon dioprotective properties. We tested the hypothesis that these and isoflurane on cardiac remodeling after perioperative myo- anesthetics positively influence myocardial remodeling 28 cardial infarction. This study determined the long-term effects days after experimental perioperative myocardial infarction of anesthetic preconditioning on cardiac remodeling after perioperative myocardial infarction using a rat model of left and compared their effects. ventricular ischemia-reperfusion injury. Methods: A total of 60 male Sprague–Dawley rats were sub- jected to 60 min of coronary artery occlusion and 120 min of reperfusion. Prior to ischemia, the animals were random- ized for the different narcotic regimes (0.6 vol% isoflurane, What This Article Tells Us That Is New 70 vol% xenon, or intraperitoneal injection of s-ketamine). • Compared to isoflurane, xenon limited adverse cardiac re- Acute injury was quantified by echocardiography and tro- modeling and contractile dysfunction after perioperative myo- cardial infarction. ponin I. After 4 weeks, left ventricular function was assessed by conductance catheter to quantify hemodynamic compro- mise. Cardiac remodeling was characterized by quantifica- after 4 weeks. Xenon in contrast to isoflurane or ketamine tion of dilatation, hypertrophy, fibrosis, capillary density, anesthetized animals demonstrated a lower remodeling apoptosis, and expression of fetal genes (α/β myosin heavy index (0.7 ± 0.1 vs. 0.9 ± 0.3 and 1.0 ± 0.3 g/ml), better ejec- chains, α-skeletal actin, periostin, and sarco/endoplasmic reticu- tion fraction (62 ± 9 vs. 49 ± 7 and 35 ± 6%), and reduced Deepa Koshi lum Ca2+-ATPase). expression of β-myosin heavy chain and periostin. The effects Results: Whereas xenon and isoflurane impeded the acute on hypertrophy, fibrosis, capillary density, and apoptosis Xenon and Cardiac Remodeling effects of ischemia-reperfusion on hemodynamics and myo- were comparable. cardial injury at a comparable level, differences were found Conclusions: Compared to isoflurane and s-ketamine, xenon limited progressive adverse cardiac remodeling and ROEHL ET AL. contractile dysfunction 28 days after perioperative myocar- dial infarction. * Anesthetist, Department of Anesthesiology, University Hos- June pital Aachen, Aachen, Germany. † Resident, Department of Anesthesiology, University Medical Center Hamburg-Eppendorf, ERIOPERATIVE myocardial infarction is a serious Hamburg, Germany. ‡ Cardiologist, Department of Cardiology, P adverse event during surgery and is associated with University Hospital Aachen. § Anesthetist, Department of Cardiac 1 2013 Surgery, University Hospital Aachen. || Research Assistant, Depart- high complication and mortality rates. Left ventricular ment of Anesthesiology, University Hospital Aachen. # Profes- remodeling following myocardial infarction leads to sor, Department of Anesthesiology, University Hospital Aachen. progressive hypertrophy, chamber dilatation, and ultimately 2013 ** Associate Professor, Department of Cardiothoracic Surgery, β Leiden University Medical Center, Leiden, The Netherlands. heart failure. Treatments that block the -adrenergic and Received from the Department of Anesthesiology, University renin–angiotensin–aldosterone system, as well as mechanical 2,3 Anesthesiology Hospital of Aken, Aachen, Germany. Submitted for publication July support, can limit or reverse this process. The extent of 20, 2012. Accepted for publication December 20, 2012. This study the remodeling process is highly dependent on the initial was supported by the German Research Foundation (Bonn, Ger- many; Fund No. Ro 2000/10–1) and Air Liquide Medical GmbH infarct size and thus could be limited by myocardial salvage 118 4 (Düsseldorf, Germany). This study was presented at the “25. Wis- achieved by reperfusion therapy. As shown in short-term senschaftliche Arbeitstage der DGAI,” Würzburg, Germany, on studies, anesthetic preconditioning not only reduces initial 6 February 11, 2011. myocardial injury,5,6 but also prevents activation of the Address correspondence to Dr. Hein: Department of Anes- 7 thesiology, University Hospital of Aken, Pauwelsstrasse 30, 52074 deleterious gene expression profile. However, long-term 1385 Aachen, Germany. [email protected]. Information on purchasing effects of anesthetic preconditioning on cardiac remodeling reprints may be found at www.anesthesiology.org or on the mast- with respect to long-term function after transient ischemia head page at the beginning of this issue. ANESTHESIOLOGY’S articles are made freely accessible to all readers, for personal use only, 6 have yet to be identified. Therefore, we used a rat model of left 94 months from the cover date of the issue. ventricular ischemia-reperfusion (IR) injury to examine the Copyright © 2013, the American Society of Anesthesiologists, Inc. Lippincott effects of isoflurane and xenon anesthesia on cardiac function, Williams & Wilkins. Anesthesiology 2013; 118:1385-94 structure, and expression of fetal genes after 4 weeks. Anesthesiology, V 118 • No 6 1385 June 2013 <zdoi;10.1097/ALN.0b013e31828744c0> Xenon and Cardiac Remodeling Materials and Methods ropivacaine (Astra Zeneca, Wedel, Germany). Metamizole Animals (Ratiopharm, Ulm, Germany) was injected intraperitoneally A total of 60 male Sprague–Dawley rats (10–12 weeks old, (20 mg/kg) and added to the tap water (10 mg/ml/kg) for 3 350–420 g) were purchased from Charles River Laborato- days. The rats were transferred to a warm isolation chamber ries (Charles River, Sulzfeld, Germany). All of the experi- (Vetario S10 Intensive Care Unit, Brinsea, Sandford, United ments were performed in accordance with the German Kingdom) for recovery. legislation governing animal studies, followed The Principles of Laboratory Animal Care (National Institute of Health, Instrumentation on Day 28 publication No. 85-23, revised in 1996), and had prior Anesthesia was induced with a reduced intraperitoneal approval by the governmental animal care and use office dosage of s-ketamine (120 mg/kg). A three-lead electro- (Landesamt für Natur, Umwelt und Verbraucherschutz Nor- cardiogram was obtained and a third echocardiographic Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/118/6/1385/260290/20130600_0-00026.pdf by guest on 24 September 2021 drhein-Westfalen, Recklinghausen, Germany, Protocol No. examination performed. The animals were intubated and 9.93.2.10.35.07.210). ventilated as on the first day. The right jugular vein was cath- eterized, and a 2F conductance catheter (SPR-869, Millar Instrumentation and Protocol on Day 0 Instruments, Houston, TX) was inserted via the right carotid After induction of anesthesia by an intraperitoneal injection artery into the left ventricle. Parallel conductivity was deter- µ of 200 mg/kg s-ketamine (Pfizer, Berlin, Germany), a three- mined by three intravenous injections of 100 L 10% saline. lead electrocardiogram was installed, and the first echocar- Pressure volume loops were recorded during apnea and grad- diographic examination with a 10-MHz probe (Vivid I, GE, ual, short-term reduction of preload. To this end, the infe- Solingen Germany) was performed. The animals were orally rior caval vein was compressed with a cotton bud through a intubated and ventilated with 30% oxygen and 70% nitro- small subxiphoidal incision. After hemodynamic measure- gen in a pressure-controlled mode with a positive end-expi- ments and blood withdrawal, the animals were killed by intravenous injection of potassium chloride and the heart ratory pressure of 5 cm H2O using a closed-circuit anesthesia machine to control the end-tidal carbon dioxide concentra- was excised for further analysis. tion (Physioflex®, Draeger, Luebeck, Germany). The left jug- ular vein was catheterized with a 22G cannula (Leader Flex, Hemodynamic Calculations Vygon, Aachen, Germany) for fluid replacement (10 ml ∙ All signals were collected at a sampling rate of 1000 Hz using kg−1 ∙ h−1 Ringer’s solution) and blood withdrawal. The anes- a data acquisition system (Power Lab 8/30, ADInstruments, thetic depth was evaluated every 30 min by tail pinch. In case Colorado Springs, CO). Time intervals of 10 s were analyzed of limb movement or an increase in heart rate (HR), 50 mg/ with dedicated software (LabChart 6 Pro, ADInstruments kg s-ketamine was injected intraperitoneally. Blood pressure GmbH, Spechbach, Germany; Circlab 2010, Paul Steendijk, was monitored by a 1.4F pressure catheter (SPR-671, Millar Leiden, The Netherlands) at the following time points (see Instruments, Houston, TX) through the right femoral artery. fig.1): At baseline (T0), 50 min after application of inhalative The animals were placed on a feedback-controlled heating narcotics just before start of ischemia (T1), 50 min after pad to maintain the body temperature at 37°C (TCAT-2 induction
Load more

Recommended publications
  • Effect of Insulin Resistance on Left Ventricular Remodeling in Essential Indicates Posterior Wall Thickness
    Bernard KP, et al., J Cardiol Stud Res 2021, 6: 018 DOI: 10.24966/CSR-768X/100018 HSOA Journal of Cardiology: Study & Research Cross-Sectional Study 9.8 years) had normal left ventricular geometry, concentric left Effect of Insulin Resistance on ventricular remodeling and concentric left ventricular hypertrophy respectively. In multivariable adjusted analysis 46.8% of variation in Left Ventricular Remodeling interventricular septum diameter (R² = 0.468; overall p ˂ 0.001), and 30.9% in E-wave deceleration time (R² =0.309; overall p = 0.003) in Essential Hypertensives: A were explained by insulin and HOMAIR, 30.1% of variation in left ventricular end-diastolic diameter(R² = 0.301; p= 0.013) by HOMAIR Cross Sectional Study alone and 46.3% of posterior wall thickness (R² = 0.463; p= 0.002) and 29.4% ofrelative wall thickness (R² = 0.294 ; p= 0.007) by insulin alone. Kianu Phanzu Bernard1,2*, , Nkodila Natuhoyila Aliocha3, Kintoki Conclusion: Insulin resistance and hyperinsulinemia do not have Vita Eleuthère1, Longo-Mbenza Benjamin1 and M’Buyamba the same influence on the components of Devereux’s formula. 1 Kabangu Jean-René Insulin resistance appears to act on the left ventricular end diastole 1Cardiology Unit, Department of internal Medicine, University of Kinshasa diameter, while hyperinsulinemia affects the posterior wall thickness. Hospital, Kinshasa, DR Congo Both abnormalities act on the interventricular septum and contribute to diastolic dysfunction via the E wave deceleration time. 2Centre Médical de Kinshasa (CMK), Kinshasa, DR Congo Keywords: Diastolic dysfunction; Hyperinsulinemia; Hypertension; 3School of Public Health, Department of Biostatistics, Kinshasa, DR Congo Insulin resistance; Left ventricular remodeling Background Abstract Hypertensive patients with Insulin Resistance (IR) are at increased Background: In clinical practice, left ventricular hypertrophy is cardiovascular risk compared to hypertensive patients without defined not by the left ventricular walls thickness, but by the left IR [1].
    [Show full text]
  • First Xenon-Xenon Collisions in the Lhc
    9th International Particle Accelerator Conference IPAC2018, Vancouver, BC, Canada JACoW Publishing ISBN: 978-3-95450-184-7 doi:10.18429/JACoW-IPAC2018-MOPMF039 FIRST XENON-XENON COLLISIONS IN THE LHC M. Schaumann∗, R. Alemany-Fernandez, P. Baudrenghien, T. Bohl, C. Bracco, R. Bruce, N. Fuster-Martinez, M. A. Jebramcik, J.M. Jowett, T. Mertens, D. Mirarchi, S. Redaelli, B. Salvachua, M. Solfaroli, H. Timko, J. Wenninger, CERN, Geneva, Switzerland Abstract EXECUTION OF THE RUN In 2017, the CERN accelerator complex once again demonstrated its flexibility by producing beams of a new A total of about 18 h of LHC time were taken for the Xe ion species, xenon, that were successfully injected into LHC. collision run. The schedule was designed to include set-up, On 12 October, collisions of fully stripped xenon nuclei first injection, validation and physics data taking. A further 12 h were devoted to experiments on crystal collimation, de- were recorded for the first time in the LHC√ at a centre-of- scribed elsewhere [3]. This tight schedule was only feasible mass energy per colliding nucleon pair of sNN = 5.44 TeV. Physics data taking started 9.5hafter the first injection of by drastically reducing the complexity of the set-up follow- xenon beams and lasted a total of 6h. The integrated lumi- ing the model of the p–Pb pilot run in September 2012 [4,5] nosity delivered to the four LHC experiments was sufficient when first injection, validation and physics data-taking were that new physics results can be expected soon. We provide achieved within a single fill.
    [Show full text]
  • XENON X-1100 High-Intensity Pulsed Light System
    XENON X-1100 High-Intensity Pulsed Light System The low cost R&D tool for investigating the applicability of Pulsed Light for new and emerging applications. The tool that researchers, scientists and engineers have been looking for is here. An easy-to-use photonic system developed by XENON that will open new doors and lead to new discoveries. The power of Pulsed Light In virtually all disciplines of science and technology there are applications where precise delivery of energy is demanded. One less studied energy delivery mechanism is the use of high-intensity pulsed light. At present the most prevalent example of this is in the use of lasers. However, the point source, coherent and single wavelength nature of lasers, are often not suited to the majority of challenges facing many industries. In these situations, it is crucial to have a broad spectra source so as not to be restricted in choosing materials with specific absorption characteristics. Because XENON sources generate light which extends from the deep UV to IR and often with peak pulse powers measured in megawatts, the ability of these sources to perform tasks such as breaking chemical bonds, sintering, ablating or sterilizing is highly realizable. The high peak powers generated by XENON’s production level systems are possible by tightly controlling the pulse durations measured from a few microseconds to milliseconds. Until now there was no practical method of generating this intense pulsed light in a low-cost R&D tool that was safe, compact and versatile. XENON has developed a system to address this challenge based on over 50 years of exper- tise in the Pulsed Light industry.
    [Show full text]
  • Pharmacology – Inhalant Anesthetics
    Pharmacology- Inhalant Anesthetics Lyon Lee DVM PhD DACVA Introduction • Maintenance of general anesthesia is primarily carried out using inhalation anesthetics, although intravenous anesthetics may be used for short procedures. • Inhalation anesthetics provide quicker changes of anesthetic depth than injectable anesthetics, and reversal of central nervous depression is more readily achieved, explaining for its popularity in prolonged anesthesia (less risk of overdosing, less accumulation and quicker recovery) (see table 1) Table 1. Comparison of inhalant and injectable anesthetics Inhalant Technique Injectable Technique Expensive Equipment Cheap (needles, syringes) Patent Airway and high O2 Not necessarily Better control of anesthetic depth Once given, suffer the consequences Ease of elimination (ventilation) Only through metabolism & Excretion Pollution No • Commonly administered inhalant anesthetics include volatile liquids such as isoflurane, halothane, sevoflurane and desflurane, and inorganic gas, nitrous oxide (N2O). Except N2O, these volatile anesthetics are chemically ‘halogenated hydrocarbons’ and all are closely related. • Physical characteristics of volatile anesthetics govern their clinical effects and practicality associated with their use. Table 2. Physical characteristics of some volatile anesthetic agents. (MAC is for man) Name partition coefficient. boiling point MAC % blood /gas oil/gas (deg=C) Nitrous oxide 0.47 1.4 -89 105 Cyclopropane 0.55 11.5 -34 9.2 Halothane 2.4 220 50.2 0.75 Methoxyflurane 11.0 950 104.7 0.2 Enflurane 1.9 98 56.5 1.68 Isoflurane 1.4 97 48.5 1.15 Sevoflurane 0.6 53 58.5 2.5 Desflurane 0.42 18.7 25 5.72 Diethyl ether 12 65 34.6 1.92 Chloroform 8 400 61.2 0.77 Trichloroethylene 9 714 86.7 0.23 • The volatile anesthetics are administered as vapors after their evaporization in devices known as vaporizers.
    [Show full text]
  • Left Ventricular Remodeling and Myocardial Work: Results from the Population-Based STAAB Cohort Study
    ORIGINAL RESEARCH published: 11 June 2021 doi: 10.3389/fcvm.2021.669335 Left Ventricular Remodeling and Myocardial Work: Results From the Population-Based STAAB Cohort Study Floran Sahiti 1,2, Caroline Morbach 1,2, Vladimir Cejka 1, Judith Albert 1,2, Felizitas A. Eichner 1,3, Götz Gelbrich 1,3,4, Peter U. Heuschmann 1,3,4† and Stefan Störk 1,2*† on behalf of the STAAB Consortium 1 Comprehensive Heart Failure Center, University and University Hospital Würzburg, Würzburg, Germany, 2 Department of Medicine I, University Hospital Würzburg, Würzburg, Germany, 3 Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany, 4 Clinical Trial Center, University Hospital Würzburg, Würzburg, Germany Edited by: Matteo Cameli, Introduction: Left ventricular (LV) dilatation and LV hypertrophy are acknowledged University of Siena, Italy precursors of myocardial dysfunction and ultimately of heart failure, but the implications of Reviewed by: Leonid Goubergrits, abnormal LV geometry on myocardial function are not well-understood. Non-invasive LV Charité – Universitätsmedizin myocardial work (MyW) assessment based on echocardiography-derived pressure-strain Berlin, Germany Sabina Gallina, loops offers the opportunity to study detailed myocardial function in larger cohorts. We University of Studies G. d’Annunzio aimed to assess the relationship of LV geometry with MyW indices in general population Chieti and Pescara, Italy free from heart failure. *Correspondence: Stefan Störk Methods and Results: We report cross-sectional baseline data from the [email protected] Characteristics and Course of Heart Failure Stages A-B and Determinants of Progression †These authors have contributed (STAAB) cohort study investigating a representative sample of the general population equally to this work of Würzburg, Germany, aged 30–79 years.
    [Show full text]
  • Xenon Gas Xe Safety Data Sheet SDS P4677
    Xenon Safety Data Sheet P-4677 This SDS conforms to U.S. Code of Federal Regulations 29 CFR 1910.1200, Hazard Communication. Date of issue: 01/01/1979 Revision date: 10/24/2016 Supersedes: 10/02/2014 SECTION: 1. Product and company identification 1.1. Product identifier Product form : Substance Name : Xenon CAS No : 7440-63-3 Formula : Xe Other means of identification : Xenon 1.2. Relevant identified uses of the substance or mixture and uses advised against Use of the substance/mixture : Industrial use. Use as directed. 1.3. Details of the supplier of the safety data sheet Praxair, Inc. 10 Riverview Drive Danbury, CT 06810-6268 - USA T 1-800-772-9247 (1-800-PRAXAIR) - F 1-716-879-2146 www.praxair.com 1.4. Emergency telephone number Emergency number : Onsite Emergency: 1-800-645-4633 CHEMTREC, 24hr/day 7days/week — Within USA: 1-800-424-9300, Outside USA: 001-703-527-3887 (collect calls accepted, Contract 17729) SECTION 2: Hazard identification 2.1. Classification of the substance or mixture GHS-US classification Compressed gas H280 2.2. Label elements GHS-US labeling Hazard pictograms (GHS-US) : GHS04 Signal word (GHS-US) : WARNING Hazard statements (GHS-US) : H280 - CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED OSHA-H01 - MAY DISPLACE OXYGEN AND CAUSE RAPID SUFFOCATION Precautionary statements (GHS-US) : P202 - Do not handle until all safety precautions have been read and understood P271+P403 - Use and store only outdoors or in a well-ventilated place CGA-PG05 - Use a back flow preventive device in the piping CGA-PG10 - Use only with equipment rated for cylinder pressure CGA-PG06 - Close valve after each use and when empty CGA-PG02 - Protect from sunlight when ambient temperature exceeds 52°C (125°F) 2.3.
    [Show full text]
  • Lung Ventilation - Xenon
    Lung Ventilation - Xenon Special Instructions Patients with severe dyspnea may not be able to tolerate this examination. To be performed only at UNMH. Radiopharmaceutical: Xe-133 gas Dose (Adult/Pediatric): Refer to Nuclear Medicine Dose Chart Route of Administration: Inhalation from a Xe-133 gas delivery system. Patient Preparation: None. Equipment Setup: Gamma Camera: ZOOM as appropriate for small children Collimator: Orbiter: LEAP SPECT-CT/ECAM/Evo/Symbia E: High resolution Computer setup: • Static acquisition • 128 x 128 matrix • Zoom 1.0 (greater for small children)—ensure that the lungs fill a significant portion of the detector for small patients • 10 sec/image for inspiration • 30 sec/image for all other images Patient Positioning: Orbiter: • Seated upright on a stool (preferred) with the detector posterior to the patient. Supine if necessary All others: • Supine Procedure: • If the patient is able to sit upright on a stool for the examination, perform the ventilation portion of the examination on the Orbiter if available. • Before beginning the study, explain the breathing maneuvers required; the patient should rehearse these maneuvers. • Place the mask on the patient and ensure that it fits snugly. • Inspiration (Single-breath) Image: • Instruct the patient to exhale completely and then to take a deep breath as the Xe-133 gas flows in. • The patient should hold his/her breath for 10 sec (if possible) while posterior (and anterior if on a dual-headed camera) imaging is performed. Revised 2017-01 Lung Ventilation - Xenon (continued) • Equilibrium (Rebreathing/Wash-in) Images: • The patient should then breathe normally for 3 images (90 seconds).
    [Show full text]
  • Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: an Overview of Current Knowledge
    Journal of Clinical Medicine Review Left Ventricular Remodeling in Hypertrophic Cardiomyopathy: An Overview of Current Knowledge Beatrice Musumeci, Giacomo Tini , Domitilla Russo, Matteo Sclafani, Francesco Cava, Alessandro Tropea, Carmen Adduci, Francesca Palano, Pietro Francia and Camillo Autore * Cardiology, Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, Sapienza University of Rome, 00189 Rome, Italy; [email protected] (B.M.); [email protected] (G.T.); [email protected] (D.R.); [email protected] (M.S.); [email protected] (F.C.); [email protected] (A.T.); [email protected] (C.A.); [email protected] (F.P.); [email protected] (P.F.) * Correspondence: [email protected]; Tel.: +39-06-3377-5577 Abstract: While most patients with hypertrophic cardiomyopathy (HCM) show a relatively stable morphologic and clinical phenotype, in some others, progressive changes in the left ventricular (LV) wall thickness, cavity size, and function, defined, overall, as “LV remodeling”, may occur. The interplay of multiple pathophysiologic mechanisms, from genetic background to myocardial ischemia and fibrosis, is implicated in this process. Different patterns of LV remodeling have been recognized and are associated with a specific impact on the clinical course and management of the disease. These findings underline the need for and the importance of serial multimodal clinical and instrumental evaluations to identify and further characterize the LV remodeling phenomenon. A more complete definition of the stages of the disease may present a chance to improve the management of Citation: Musumeci, B.; Tini, G.; Russo, D.; Sclafani, M.; Cava, F.; HCM patients. Tropea, A.; Adduci, C.; Palano, F.; Francia, P.; Autore, C.
    [Show full text]
  • Active Moiety Name FDA Established Pharmacologic Class (EPC) Text
    FDA Established Pharmacologic Class (EPC) Text Phrase PLR regulations require that the following statement is included in the Highlights Indications and Usage heading if a drug is a member of an EPC [see 21 CFR 201.57(a)(6)]: “(Drug) is a (FDA EPC Text Phrase) indicated for [indication(s)].” For Active Moiety Name each listed active moiety, the associated FDA EPC text phrase is included in this document. For more information about how FDA determines the EPC Text Phrase, see the 2009 "Determining EPC for Use in the Highlights" guidance and 2013 "Determining EPC for Use in the Highlights" MAPP 7400.13. .alpha.
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Xenon-Tried-Tested-And-True.Pdf
    Tried, tested and true: Why Xenon illumination is the preferred choice over laser phosphor for mainstream cinema Xenon – cinema’s workhorse With 45 years of use and 1.5 million installations worldwide, Christie® Xenolite® lamps are a constant in the cinema industry. Producing impressive light output, accurate color reproduction and boasting 99.999% reliability, this “lightning in a bottle” technology is the dependable workhorse trusted by exhibitors everywhere. Laser phosphor cinema projectors – not to be confused with RGB laser projectors – have been touted as a viable option to replace Xenon-based systems. This has resulted in cinema owners being faced with a decision. Should they continue using Xenon lamps, or make the switch to laser phosphor? Our answer to this is simple. For mainstream theatres, laser phosphor cinema projectors do not provide the performance advantages to justify them as an acceptable option over Xenon-based systems. Brightness over 30,000 hours 20K lumen-class, Xenon versus laser phosphor* 110% (Number of lamps used) (14 fL) 100% 1 2 3 4 5 6 7 8 9 10 11 Xenon 90% 11 fL typical (11 fL) 80% â Below DCI standards Just over 1 year á 70% of operation (based on 10 hours per day) 60% DCI Laser phosphor 7.0 fL typical ed brightness 50% ent of rc quir Pe re 0% 052,800 ,600 8,400 11,200 14,000 16,800 19,600 22,400 25,200 28,000 30,800 Hours of operation * ~20m wide screen * ~1.8 gain screen Laser phosphor – not suitable for cinema laser phosphor projectors.
    [Show full text]
  • Cardiac Surgery a Guide for Patients and Their Families Welcome to the Johns Hopkins Hospital
    HEART AND VASCULAR INSTITUTE Cardiac Surgery A guide for patients and their families Welcome to The Johns Hopkins Hospital We are providing this book to you and your family to guide you through your surgical experience at the Johns Hopkins Heart and Vascular Institute. The physicians, nurses and other health care team members strive to provide you with the safest and best medical care possible. Please do not hesitate to ask your surgeon, nurse or other health care team member any questions before, during and after your operation. The booklet consists of two major sections. The first section informs you about the surgery and preparing for the hospital stay. The second section prepares you for the recovery period after surgery in the hospital and at home. TABLE OF CONTENTS Welcome to Johns Hopkins Cardiac Surgery 1 The Function of the Heart 2 Who’s Taking Care of You 3 Heart Surgery 4 Preparation for Surgery 5 Preoperative Testing and Surgical Consultation 7 The Morning of Surgery 9 After Surgery 10 Going Home After Cardiac Surgery 19 How We Help with Appointments and 24 Other Arrangements for Out-of-Town Patients Appendix 25 Looking back, it was the choice of my life. It’s not easy to put your heart in someone else’s hands. But for me, the choice was clear: I trusted it to Hopkins. My Heart. My Choice Patient Lou Grasmick, Founder & CEO, Louis J. Grasmick Lumber Company, Inc. Welcome to Johns Hopkins Cardiac Surgery The Johns Hopkins Hospital has a distinguished history of advancements in the treat- ment of cardiovascular diseases in adults and children, beginning with the Blalock-Taussig shunt in 1944.
    [Show full text]